Hematologic Oncology | Specialty

FDA Grants Eprenetapopt Fast Track Status in TP53-Mutant AML

November 30th 2020

November 30, 2020 - The FDA has granted a fast track designation to eprenetapopt as a treatment for patients with TP53-mutant acute myeloid leukemia.

FDA Grants Belumosudil Priority Review for Chronic GVHD

November 30th 2020

The FDA has granted a priority review designation to a new drug application for belumosudil for the treatment of patients with chronic graft-versus-host disease.

Panelists Parse Out Answers to Key Questions in Hematologic Malignancies

November 25th 2020

Stephen A. Strickland, MD, BS, MS, MSCI, relays insightful questions from the audience to the speakers, who provided insight into how they are navigating the evolving treatment landscape of hematologic malignancies.

Dr. Dorritie on Determining Transplant Eligibility in Multiple Myeloma

November 24th 2020

Kathleen ​A. Dorritie, MD, discusses transplant eligibility in multiple myeloma.

CAR T-Cell Therapy Transforms Leukemia and Lymphoma Treatment, But Toxicity Concerns Remain

November 24th 2020

Olalekan O. Oluwole, MBBS, MD, discusses the approvals of tisagenlecleucel and axicabtagene ciloleucel, along with several research efforts that have been dedicated to the development and exploration of CAR T-cell therapies in the realm of leukemias and lymphomas.

NCCN Grants Category 2A Recommendation to Decitabine/Cedazuridine Combo for MDS

November 23rd 2020

November 23, 2020 - The National Comprehensive Cancer Network has updated its Clinical Practice Guidelines in Oncology for Myelodysplastic Syndromes (MDS) to include the combination of decitabine and cedazuridine as a category 2a recommendation for the treatment of adult patients with intermediate- and high-risk MDS.

Dr. Dean on Remaining Challenges in DLBCL

November 19th 2020

Robert M. Dean, MD, discusses remaining challenges in diffuse large B-cell lymphoma.

FDA Grants Rilzabrutinib Fast Track Designation for Immune Thrombocytopenia

November 18th 2020

November 18, 2020 - The FDA has granted a fast track designation to the BTK inhibitor rilzabrutinib for the treatment of patients with immune thrombocytopenia.

The Future of MDS Management

November 18th 2020

Overview of Luspatercept-aamt as MDS Treatment

November 18th 2020

The Role of Hypomethylating Agents and Transplantation

November 18th 2020

Initiating First-Line Treatment

November 18th 2020

The Role of Supportive Care 

November 18th 2020

IPSS/IPSS-R Reliability in Various Disease Settings 

November 18th 2020

Disease-Course Differentiation: Low Risk and High Risk

November 18th 2020

Challenges of MDS Management

November 18th 2020

Ensuring an Accurate Diagnosis

November 18th 2020

Heterogeneity and Presentation of MDS

November 18th 2020

COVID-19 Delays FDA Review of Liso-Cel for Relapsed/Refractory Large B-Cell Lymphoma

November 17th 2020

November 17, 2020 - The review of the biologics license application for the CAR T-cell product lisocabtagene maraleucel for the treatment of adult patients with relapsed/refractory large B-cell lymphoma following at least 2 previous therapies has been delayed.

NICE Recommends Caplacizumab for Acute Acquired Thrombotic Thrombocytopenic Purpura

November 16th 2020

November 16, 2020 — The United Kingdom’s National Institute for Health and Care Excellence has recommended caplacizumab-yhdp with plasma exchange and immunosuppression for the treatment of an acute episode of acquired thrombotic thrombocytopenic purpura in adults and those aged 12 years and over who weigh at least 40 kg.